Publications by authors named "Eva Axen"

Claim this Profile
P
Patient-Reported Outcomes for Glabellar Line Improvement and Satisfaction With the RelabotulinumtoxinA Ready-to-Use Liquid Formulation: Data From the Phase 3 READY-1 Trial.
Michael H Gold, Lisa Donofrio, Sachin Shridharani, Amir Moradi, Brian Biesman

Aesthet Surg J· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines.
Sachin M Shridharani, Amir Moradi, Lisa Donofrio, Michael H Gold, Brian Biesman

Aesthet Surg J· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-Benzyl-indolo carboxylic acids: Design and synthesis of potent and selective adipocyte fatty-acid binding protein (A-FABP) inhibitors.
Tjeerd Barf, Fredrik Lehmann, Kristin Hammer, Saba Haile, Eva Axen

Bioorg Med Chem Lett· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target.
Fredik Lehmann, Saba Haile, Eva Axen, Carmen Medina, Jonas Uppenberg

Bioorg Med Chem Lett· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substituted benzylamino-6-(trifluoromethyl)pyrimidin-4(1H)-ones: a novel class of selective human A-FABP inhibitors.
Rune Ringom, Eva Axen, Jonas Uppenberg, Thomas Lundbäck, Lena Rondahl

Bioorg Med Chem Lett· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis